Literature DB >> 32303520

Diabetes-induced eye disease among First Nations people in Ontario: a longitudinal, population-based cohort study.

Robert J Campbell1, Roseanne Sutherland2, Shahriar Khan2, Katharine M Doliszny2, Philip L Hooper2, Morgan Slater2, Eliot Frymire2, Baiju R Shah2, Jennifer D Walker2, Michael E Green2.   

Abstract

BACKGROUND: In Canada, First Nations populations experience a higher incidence of diabetes and diabetes-related complications than other people. Given the paucity of information on use of preventive eye examinations and the need for interventional care for severe retinopathy among First Nations people, we carried out a population-based study to compare rates of eye examinations and interventional therapies to treat vision-threatening stages of diabetic retinopathy among First Nations people and other people with diabetes in Ontario.
METHODS: In collaboration with the Chiefs of Ontario, we carried out a population-based study to identify cohorts of First Nations people and other people with diabetes in Ontario from 1995/96 to 2014/15. We used linked health administrative databases to evaluate rates of eye examination (2005/06-2014/15) and severe diabetic retinopathy treatment and compared them between the 2 populations, and between First Nations people living in and outside of First Nations communities.
RESULTS: We identified 23 013 First Nations people and 1 364 222 other people diagnosed with diabetes from 1995/96 to 2014/15, of whom 49.8% (95% confidence interval [CI] 48.9%-50.7%) and 53.8% (95% CI 53.7%-54.0%), respectively, received an eye examination in 2014/15. Eye examination rates were similar for First Nations people regardless of whether they lived in or outside a First Nations community. First Nations people developed severe diabetic retinopathy at a faster rate than other people (hazard ratio 1.19, 95% CI 1.02-1.38). The gap between First Nations people and other people in the proportion requiring therapy for severe diabetic retinopathy was especially prominent among younger people. There were no significant differences in rates of diabetic retinopathy treatment in First Nations people stratified by place of residence.
INTERPRETATION: Eye examination rates remain suboptimal among people with diabetes in Ontario and were lower among First Nations people. This is particularly concerning in light of our other findings showing an increased risk of requiring treatment for advanced diabetic retinopathy and the accelerated rate of diabetic retinopathy progression among First Nations people with diabetes. Copyright 2020, Joule Inc. or its licensors.

Entities:  

Year:  2020        PMID: 32303520      PMCID: PMC7207040          DOI: 10.9778/cmajo.20200005

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  30 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

Review 2.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

3.  Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors.

Authors:  Anthony J G Hanley; Stewart B Harris; Mary Mamakeesick; Ken Goodwin; Edith Fiddler; Robert A Hegele; J David Spence; Andrew A House; Ed Brown; Blair Schoales; John R McLaughlin; Ronald Klein; Bernard Zinman
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

4.  Report summary. Diabetes in Canada: facts and figures from a public health perspective.

Authors:  C Pelletier; S Dai; K C Roberts; A Bienek; J Onysko; L Pelletier
Journal:  Chronic Dis Inj Can       Date:  2012-12

5.  Evaluation of a mobile diabetes care telemedicine clinic serving Aboriginal communities in Northern British Columbia, Canada.

Authors:  Andrew J Jin; David Martin; David Maberley; Keith G Dawson; David W Seccombe; Joyce Beattie
Journal:  Int J Circumpolar Health       Date:  2004       Impact factor: 1.228

6.  Identification of diabetic retinopathy by stereoscopic digital imaging via teleophthalmology: a comparison to slide film.

Authors:  M T Tennant; M D Greve; C J Rudnisky; T R Hillson; B J Hinz
Journal:  Can J Ophthalmol       Date:  2001-06       Impact factor: 1.882

7.  The current status of diabetes care, diabetic retinopathy screening and eye-care in British Columbia's First Nations Communities.

Authors:  Harrup Kaur; David Maberley; Angela Chang; Dawn Hay
Journal:  Int J Circumpolar Health       Date:  2004-09       Impact factor: 1.228

8.  Monitoring, treatment and control of blood glucose and lipids in Ontario First Nations people with diabetes.

Authors:  Michael E Green; Baiju R Shah; Morgan Slater; Shahriar Khan; Carmen R Jones; Jennifer D Walker
Journal:  CMAJ       Date:  2020-08-17       Impact factor: 8.262

9.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

10.  Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

Authors:  Robert J Campbell; Sudeep S Gill; Susan E Bronskill; J Michael Paterson; Marlo Whitehead; Chaim M Bell
Journal:  BMJ       Date:  2012-07-04
View more
  2 in total

1.  Impact of the COVID-19 Pandemic on Diabetes Care for Adults With Type 2 Diabetes in Ontario, Canada.

Authors:  John S Moin; Natalie Troke; Lesley Plumptre; Geoffrey M Anderson
Journal:  Can J Diabetes       Date:  2022-05-02       Impact factor: 2.774

2.  Monitoring, treatment and control of blood glucose and lipids in Ontario First Nations people with diabetes.

Authors:  Michael E Green; Baiju R Shah; Morgan Slater; Shahriar Khan; Carmen R Jones; Jennifer D Walker
Journal:  CMAJ       Date:  2020-08-17       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.